Designing and synthesising therapeutic oligonucleotides for drug developers
Oligonucleotide medicines must remain stable and reach the cells they are intended to treat. Entering cells and crossing their internal membranes to reach molecular targets remain major delivery challenges, requiring attention to both drug chemistry and formulation.
NAXIA Discovery designs, synthesises and formulates therapeutic oligonucleotides. Its services and co-development model give academic and industry teams access to oligonucleotide chemistry expertise for early drug discovery.
What stands out about NAXIA Discovery
Co-founded by Professor Philippe Barthélémy, whose ARNA laboratory originated the therapeutic oligonucleotide discovery platform.
Spun out from academic and translational research to develop a chemistry-driven oligonucleotide discovery platform.
Co-founder Nicolas Babault previously founded ELBA Discovery, a consultancy specialising in therapeutic drug discovery and preclinical development.
Won the Spartners by Servier & BioLabs Award at the 2025 BioFIT Start-up Slams, with strategic support and access to laboratory environments.
Won the Innovation Award in the 2025 Neighborhood programme run by Voisin Consulting Life Sciences.
Participated in the 2025 Neighborhood acceleration programme by Voisin Consulting Life Sciences, providing yearlong strategic and regulatory mentoring.
Tell us about your company and what you're looking to achieve.